I’m a little late to publishing this— but these went around on twitter a month ago— and pandemic life is just crazy.
But I can’t miss actually writing a post to what is a huge milestone for a new laboratory: the first paper to come out of the lab on the work done one of the amazing graduate student trainees that I’m privileged to mentor: Maria Palafox. Maria is co-mentored by myself and my colleague, Keriann Backus, and she’s been working at the intersection of our labs:
As a geneticist, I had never given much thought to proteins until the end of a project when we aim to functionally validate a genetic variant. But learning more about the exciting world of chemoproteomics— we have started to work on how integration of genomic annotations and chemoproteomics data sets presents a powerful tool to identify novel biology, particularly when it comes to functionally validating missense variation.
Our study provides a roadmap for more precise inter-database comparisons and points to untapped opportunities to improve the predictive power of pathogenicity scores and to advance prioritization of putative druggable sites through integration of predictions of pathogenicity with chemoproteomic datasets.
See the full study here and let us know what you think!